Doxorubicin (DOX) constitutes the major constituent of anti-cancer treatment regimens
currently in clinical use. However, the precise mechanisms of DOX's action are not fully …

Elastin-like polypeptides (ELPs) are stimulus-responsive biopolymers derived from human
elastin. Their unique properties—including lower critical solution temperature phase …

Chemotherapy causes off‐target toxicity and is often ineffective against solid tumors.
Targeted and on‐demand release of chemotherapeutics remains a challenge. Here, cancer …

Lung metastasis is challenging in patients with triple‐negative breast cancer (TNBC).
Surgery is always not available due to the dissemination of metastatic foci and most drugs …

Chemotherapy has been a conventional paradigm for cancer treatment, and multifarious
chemotherapeutic drugs have been widely employed for decades with significant …

The term 'immunogenic cell death'(ICD) denotes an immunologically unique type of
regulated cell death that enables, rather than suppresses, T cell-driven immune responses …

Nanomaterials and targeted drug delivery vehicles improve the therapeutic index of drugs
and permit greater control over their pharmacokinetics, biodistribution, and bioavailability …

Nanoscience has long been lauded as a method through which tumor-associated barriers
could be overcome. As successful as cancer immunotherapy has been, limitations …

As traditional strategies for cancer treatment, some chemotherapy agents, such as
doxorubicin, oxaliplatin, cyclophosphamide, bortezomib, and paclitaxel exert their anti-tumor …

Cancer immunotherapy has achieved remarkable clinical efficacy through recent advances
such as chimeric antigen receptor‐T cell (CAR‐T) therapy, immune checkpoint blockade …